AR077909A1 - Intervenciones de urgencia de carbon vegetal activo con sobredosificacion con etexilato de dabigatran - Google Patents

Intervenciones de urgencia de carbon vegetal activo con sobredosificacion con etexilato de dabigatran

Info

Publication number
AR077909A1
AR077909A1 ARP100103077A ARP100103077A AR077909A1 AR 077909 A1 AR077909 A1 AR 077909A1 AR P100103077 A ARP100103077 A AR P100103077A AR P100103077 A ARP100103077 A AR P100103077A AR 077909 A1 AR077909 A1 AR 077909A1
Authority
AR
Argentina
Prior art keywords
overdose
urgency
interventions
vegetable carbon
active vegetable
Prior art date
Application number
ARP100103077A
Other languages
English (en)
Inventor
Ryn Joanne Van
Andreas Clemens
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR077909A1 publication Critical patent/AR077909A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un método para tratar una sobredosificacion con la sustancia activa etexilato de dabigatrán de formula 1 opcionalmente en forma de sus sales farmacéuticamente aceptables, que comprende la administracion de una cantidad eficaz de carbon vegetal. Carbon vegetal; uso del carbon vegetal.
ARP100103077A 2009-08-24 2010-08-23 Intervenciones de urgencia de carbon vegetal activo con sobredosificacion con etexilato de dabigatran AR077909A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23632109P 2009-08-24 2009-08-24

Publications (1)

Publication Number Publication Date
AR077909A1 true AR077909A1 (es) 2011-09-28

Family

ID=42740360

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103077A AR077909A1 (es) 2009-08-24 2010-08-23 Intervenciones de urgencia de carbon vegetal activo con sobredosificacion con etexilato de dabigatran

Country Status (19)

Country Link
US (2) US20110206656A1 (es)
EP (1) EP2470187B1 (es)
JP (1) JP2013502449A (es)
KR (1) KR20120050457A (es)
CN (1) CN102481317B (es)
AR (1) AR077909A1 (es)
AU (1) AU2010288601A1 (es)
BR (1) BR112012004169A2 (es)
CA (1) CA2767966A1 (es)
CL (1) CL2012000488A1 (es)
DK (1) DK2470187T3 (es)
EA (1) EA201200319A1 (es)
ES (1) ES2436076T3 (es)
IL (1) IL216968A0 (es)
MX (1) MX2012001767A (es)
NZ (1) NZ597359A (es)
PL (1) PL2470187T3 (es)
TW (1) TW201124143A (es)
WO (1) WO2011023653A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
AP2013007046A0 (en) 2011-03-30 2013-08-31 Boehringer Ingelheim Int Anticoagulant antidotes
GB201120693D0 (en) * 2011-12-01 2012-01-11 Convatec Technologies Inc Wound dressing for use in vacuum therapy
CN114452839B (zh) * 2022-02-10 2023-04-21 中南大学湘雅医院 一种抗凝抗栓血液净化膜及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5277820A (en) * 1992-02-06 1994-01-11 Hemocleanse, Inc. Device and method for extracorporeal blood treatment
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
PL210862B1 (pl) 2002-03-07 2012-03-30 Boehringer Ingelheim Pharma Kompozycja farmaceutyczna w postaci peletki do doustnego podawania i sposób wytwarzania kompozycji

Also Published As

Publication number Publication date
JP2013502449A (ja) 2013-01-24
MX2012001767A (es) 2012-02-29
TW201124143A (en) 2011-07-16
US20110206656A1 (en) 2011-08-25
NZ597359A (en) 2014-01-31
BR112012004169A2 (pt) 2016-03-29
CN102481317B (zh) 2014-09-03
CL2012000488A1 (es) 2012-08-31
EP2470187A1 (en) 2012-07-04
PL2470187T3 (pl) 2014-01-31
EP2470187B1 (en) 2013-08-21
AU2010288601A1 (en) 2012-02-02
EA201200319A1 (ru) 2012-09-28
CN102481317A (zh) 2012-05-30
KR20120050457A (ko) 2012-05-18
DK2470187T3 (da) 2013-10-28
CA2767966A1 (en) 2011-03-03
IL216968A0 (en) 2012-02-29
ES2436076T3 (es) 2013-12-26
US20130302311A1 (en) 2013-11-14
WO2011023653A1 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
CY1120832T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
CL2008002999A1 (es) Uso de una composicion farmeceutica que comprende trns-clominefo para preparar un medicamenteo util en el ratamiento de recuccion de los niveles de glucosa en ayunas en un varon.
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
ES2509117T3 (es) Composición farmacéutica oral que contiene dabigatran etexilato
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
NI201000105A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada.
CL2015001461A1 (es) Una formulación estabilizada de pemetrexed.
CR20110110A (es) Composicion farmaceutica
CO7200273A2 (es) Combinaciones farmaceúticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
CR20120296A (es) Nuevos compuestos de espiropiperidina
CR20140334A (es) Forma galénica divisible que permite una liberación modificada del principio activo
BR112015002183A2 (pt) processos para a preparação de (s) -3- (4 - ((4- (morfolinometil) benzil) oxi) -1-oxoisoindolin-2-il) -piperidina-2,6-diona e formas farmaceuticamente aceitáveis da mesma
CR20120316A (es) Procesos para la fabricación de un agente farmacéuticamente activo
CO6561789A2 (es) Método de tratamiento
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
AR077909A1 (es) Intervenciones de urgencia de carbon vegetal activo con sobredosificacion con etexilato de dabigatran
ECSP11011323A (es) Método o sistema que usa biomarcadores para el seguimiento de un tratamiento.
EA201390417A1 (ru) Антидиабетические твердые фармацевтические композиции
CO6680652A2 (es) Usos terapéuticos de 1-[2-(2.4-dimetil-fenilsulfanil)fenil]piperazina
WO2013003899A8 (en) Methods of treating or preventing rheumatic disease
UY35033A (es) Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa
EA201500368A1 (ru) Фармацевтическая композиция 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей для лечения кардиоваскулярной патологии

Legal Events

Date Code Title Description
FG Grant, registration